Published in J Neurol Neurosurg Psychiatry on March 01, 2000
Toxin-induced models of Parkinson's disease. NeuroRx (2005) 2.67
Contributions of the striatum to learning, motivation, and performance: an associative account. Trends Cogn Sci (2012) 1.42
Parkinson's disease: animal models and dopaminergic cell vulnerability. Front Neuroanat (2014) 1.18
Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism. J Cereb Blood Flow Metab (2011) 0.99
Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor. BMC Biol (2004) 0.89
Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. J Neurochem (2010) 0.89
Pattern of dopaminergic loss in the striatum of humans with parkinsonism induced by MPTP. J Neurol Neurosurg Psychiatry (2000) 0.75
Parkinsonism: onset, progression and mortality. Neurology (1967) 36.06
Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (1983) 9.41
Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med (1988) 4.98
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A (1983) 3.39
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature (1988) 3.12
Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (1990) 2.45
Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol (1989) 2.33
Multiple system atrophy with autonomic failure: clinical, histological and neurochemical observations on four cases. J Neurol Sci (1979) 1.92
Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry (1991) 1.69
Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res (1990) 1.46
Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med (1994) 1.35
Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. Adv Neurol (1993) 1.25
Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature (1985) 1.14
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience (1991) 1.12
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? Neuroscience (1988) 1.12
Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol (1994) 1.11
Cognitive change following MPTP exposure. Neurology (1990) 1.05
Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A (1992) 1.04
Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci (1984) 1.01
Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? Ann Neurol (1992) 0.98
3D PET using a conventional multislice tomograph without septa. J Comput Assist Tomogr (1991) 0.98
A convolution-subtraction scatter correction method for 3D PET. Phys Med Biol (1994) 0.97
Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry (1994) 0.96
Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions. Neuroscience (1989) 0.95
The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease. Neurosci Lett (1988) 0.89
MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration. Neurosci Lett (1994) 0.88
Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys. Brain Res (1992) 0.88
Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience (1993) 0.84
The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey. Brain Res (1990) 0.81
Contrasting tissue factors predict heterogeneous striatal dopamine neurotoxicity after MPTP or methamphetamine treatment. Brain Res (1990) 0.80
MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys. Brain Res (1990) 0.78
Dopaminergic function in patients with posttraumatic parkinsonism: an 18F-dopa PET study. Neurology (1997) 0.78
Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (1983) 9.41
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science (1989) 7.03
Multiple receptors for dopamine. Nature (1979) 5.51
Parkinson disease in twins: an etiologic study. JAMA (1999) 5.45
Double-blind study of botulinum toxin in spasmodic torticollis. Lancet (1986) 4.54
Levodopa failure in chronic manganism. Neurology (1994) 3.80
Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med (1995) 3.64
Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science (2001) 3.18
The role of radiotracer imaging in Parkinson disease. Neurology (2005) 3.02
L-dopa in postencephalitic parkinsonism. Lancet (1969) 2.72
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology (2007) 2.72
A scoring error in the Mini-Mental State test. Can J Psychiatry (1993) 2.69
Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology (1985) 2.58
The Neurobehavioral Cognitive Status Examination: a brief but quantitative approach to cognitive assessment. Ann Intern Med (1987) 2.58
Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol (2001) 2.50
Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology (1983) 2.47
Bromocriptine in Parkinsonism. Br Med J (1974) 2.44
Bilateral human fetal striatal transplantation in Huntington's disease. Neurology (2002) 2.34
Aetiology of Parkinson's disease. Lancet (1984) 2.32
Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol (2001) 2.31
Subtle brain abnormalities in children with sickle cell disease: relationship to blood hematocrit. Ann Neurol (1999) 2.26
Granulocytic sarcoma in childhood leukemia: imaging features. Radiology (1994) 2.26
Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol (1990) 2.18
Smoking and Parkinson's disease in twins. Neurology (2002) 2.15
The correlation between phase shifts in gradient-echo MR images and regional brain iron concentration. Magn Reson Imaging (1999) 2.11
Vocal cord paralysis in the Shy-Drager syndrome. J Neurol Neurosurg Psychiatry (1979) 2.04
Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) N Engl J Med (1992) 2.01
Manganese neurotoxicity: a review of clinical features, imaging and pathology. Neurotoxicology (1999) 1.97
Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital. J Clin Oncol (1997) 1.94
Reaction time in Parkinson's disease. Brain (1981) 1.92
Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology (2011) 1.90
Genetic heterogeneity in familial idiopathic basal ganglia calcification (Fahr disease). Neurology (2004) 1.87
X-linked scapuloperoneal syndrome. J Neurol Neurosurg Psychiatry (1972) 1.87
Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology (2004) 1.86
L-dopa in idiopathic parkinsonism. Lancet (1969) 1.86
A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet (1998) 1.84
Hypotension caused by L-dopa. Br Med J (1970) 1.81
Positron emission tomography in manganese intoxication. Ann Neurol (1989) 1.78
Collagen XVIII, containing an endogenous inhibitor of angiogenesis and tumor growth, plays a critical role in the maintenance of retinal structure and in neural tube closure (Knobloch syndrome). Hum Mol Genet (2000) 1.76
The hypothalamus in Parkinson disease. Ann Neurol (1978) 1.74
Pten (phosphatase and tensin homologue gene) haploinsufficiency promotes insulin hypersensitivity. Diabetologia (2006) 1.72
Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res (1984) 1.71
Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov Disord (2001) 1.68
The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol (1992) 1.67
Selegiline and mortality in Parkinson's disease. Ann Neurol (1996) 1.67
Alzheimer's disease, Parkinson's disease, and motoneurone disease: abiotrophic interaction between ageing and environment? Lancet (1986) 1.65
In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol (2000) 1.65
Cardiovascular reflexes in Parkinsonism. Clin Sci (1971) 1.62
Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. Br Med J (1971) 1.60
PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology (2008) 1.60
Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study. Neurology (1996) 1.60
CFS hydroxylase cofactor levels in some neurological diseases. J Neurol Neurosurg Psychiatry (1980) 1.59
Selegiline in Parkinson's disease. BMJ (1995) 1.58
Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci (1984) 1.57
Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol (1986) 1.56
Post-traumatic stimulus suppressible myoclonus of peripheral origin. J Neurol Neurosurg Psychiatry (1998) 1.52
Motor nerve conduction velocity in peroneal muscular atrophy: evidence for genetic heterogeneity. J Neurol Neurosurg Psychiatry (1974) 1.47
Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow. Ann Neurol (1991) 1.46
Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol (1997) 1.45
Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res (1988) 1.44
Volumetric measurements of subcortical nuclei in patients with temporal lobe epilepsy. Neurology (2001) 1.44
Levodopa induces dyskinesias in normal squirrel monkeys. Ann Neurol (2001) 1.44
Parkinsonism caused by petroleum waste ingestion. Neurology (1994) 1.42
PCR analysis of platelet mtDNA: lack of specific changes in Parkinson's disease. Mov Disord (1993) 1.42
The reproducibility of striatal uptake data obtained with positron emission tomography and fluorine-18-L-6-fluorodopa tracer in non-human primates. J Nucl Med (1991) 1.42
Action of dopamine on the human iris. Br Med J (1969) 1.42
(+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA (1988) 1.41
Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med (1983) 1.40
Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain (2009) 1.40
Tremor in MPTP-induced parkinsonism. Neurology (1992) 1.39
Hereditary form of parkinsonism--dementia. Ann Neurol (1998) 1.39
Selegiline and Parkinson's disease: it's déjà vu-again. Neurology (2000) 1.37
Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med (1994) 1.35
Essential tremor. Clin Neuropharmacol (1983) 1.33
Local treatment of spasmodic torticollis with botulinum toxin. Can J Neurol Sci (1987) 1.33
Subtle white matter volume differences in children treated for medulloblastoma with conventional or reduced dose craniospinal irradiation. Magn Reson Imaging (2000) 1.31
Olfactory impairment in Parkinson's disease. Neurology (1983) 1.30
Autosomal dominant dystonia-plus with cerebral calcifications. Neurology (2006) 1.27
Lesions of the putamen and dystonia: CT and magnetic resonance imaging. Neurology (1984) 1.26
Vibratory sense: a critical review. Brain (1966) 1.26
18Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer cases, including 13 serial scans. Can J Neurol Sci (1990) 1.26
A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci (1985) 1.26
Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. Adv Neurol (1993) 1.25
Long-term treatment of parkinsonism with bromocriptine. Lancet (1978) 1.24
1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett (1984) 1.24
Nomifensine in parkinsonism. J Neurol Neurosurg Psychiatry (1976) 1.24
Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization. J Comp Neurol (2000) 1.24
Statistical list-mode image reconstruction for the high resolution research tomograph. Phys Med Biol (2004) 1.23
Pargyline prevents MPTP-induced parkinsonism in primates. Science (1984) 1.22
Chronic manganese intoxication. Arch Neurol (1989) 1.22
Idiopathic parkinsonism treated with bromocriptine. Lancet (1975) 1.20
MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects. Acta Neurol Scand Suppl (1984) 1.20
Essential tremor in twins: an assessment of genetic vs environmental determinants of etiology. Neurology (2001) 1.19